Revolution Medicines, Inc. (RVMD)
Healthcare • Biotechnology
StockNasdaqGSUnited StatesUS76155X1000
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Revolution Medicines, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 16:32. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 24 Feb 2027 16:00 | -1.15 | — | — | Upcoming |
| 04 Nov 2026 16:00 | -2.38 | -1.90 | +20.2% | Beat |
| 05 Aug 2026 16:00 | -2.06 | -3.06 | -48.8% | Miss |
| 06 May 2026 16:00 | -1.84 | -2.29 | -24.6% | Miss |
| 25 Feb 2026 16:00 | -1.56 | -1.86 | -18.9% | Miss |
| 05 Nov 2025 16:00 | -1.41 | -1.61 | -14.3% | Miss |
| 06 Aug 2025 16:00 | -1.12 | -1.31 | -16.7% | Miss |
| 07 May 2025 16:00 | -1.06 | -1.13 | -7.0% | Miss |
| 26 Feb 2025 16:00 | -0.96 | -1.12 | -16.1% | Miss |
| 06 Nov 2024 16:00 | -0.88 | -0.94 | -7.0% | Miss |
| 07 Aug 2024 16:00 | -0.76 | -0.81 | -6.3% | Miss |
| 08 May 2024 16:00 | -0.72 | -0.70 | +2.5% | Beat |
| 26 Feb 2024 16:00 | -0.88 | -1.14 | -30.3% | Miss |
| 06 Nov 2023 16:00 | -1.00 | -0.99 | +1.0% | Beat |
| 08 Aug 2023 16:00 | -0.82 | -0.92 | -12.0% | Miss |
| 08 May 2023 16:00 | -0.80 | -0.72 | +9.8% | Beat |
| 27 Feb 2023 16:00 | -0.81 | -0.63 | +22.1% | Beat |
| 07 Nov 2022 16:00 | -0.85 | -0.87 | -2.6% | Miss |
| 09 Aug 2022 16:00 | -0.84 | -0.82 | +2.9% | Beat |
| 09 May 2022 16:00 | -0.77 | -0.78 | -1.8% | Miss |
| 28 Feb 2022 16:00 | -0.64 | -0.71 | -11.8% | Miss |
| 10 Nov 2021 16:00 | -0.62 | -0.72 | -16.2% | Miss |
| 11 Aug 2021 16:00 | -0.56 | -0.60 | -7.8% | Miss |
| 10 May 2021 16:00 | -0.52 | -0.53 | -2.0% | Miss |
| 02 Mar 2021 16:00 | -0.43 | -0.52 | -22.2% | Miss |
| 12 Nov 2020 07:00 | -0.40 | -0.42 | -4.2% | Miss |
| 10 Aug 2020 07:00 | -0.37 | -0.46 | -24.6% | Miss |
| 14 May 2020 16:00 | -0.36 | -0.74 | -108.0% | Miss |
| 30 Mar 2020 16:00 | -1.39 | -6.46 | -363.5% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 0 | — | -1.1B | — | -5.95 | -66.2% | -913.7M |
| 2024 | 0 | -100.0% | -600.1M | — | -3.58 | +7.3% | -567.7M |
| 2023 | 11.6M | -67.3% | -436.4M | -3,768.3% | -3.86 | -25.3% | -358.3M |
| 2022 | 35.4M | — | -248.7M | -703.0% | -3.08 | — | -235.2M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 190.71 | 211.41 | 168.62 | 170.73 | -10.76% | 29,694,883 | |
| Oct 2026 | 204.00 | 210.88 | 175.91 | 191.31 | -6.80% | 42,541,200 | |
| Sep 2026 | 204.64 | 213.00 | 188.18 | 205.26 | -0.15% | 42,165,500 | |
| Aug 2026 | 184.43 | 224.31 | 180.14 | 205.57 | +9.62% | 38,755,600 | |
| Jul 2026 | 185.49 | 194.56 | 176.00 | 187.53 | +0.13% | 43,155,100 | |
| Jun 2026 | 159.95 | 193.10 | 141.44 | 187.28 | +18.92% | 75,638,300 | |
| May 2026 | 143.50 | 158.13 | 139.39 | 157.48 | +9.27% | 51,306,600 | |
| Apr 2026 | 98.67 | 155.70 | 94.00 | 144.12 | +48.20% | 89,430,000 | |
| Mar 2026 | 101.50 | 102.36 | 91.52 | 97.25 | -4.68% | 42,507,600 | |
| Feb 2026 | 96.52 | 107.45 | 93.02 | 102.02 | +5.23% | 45,338,900 | |
| 51 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- What Sent Revolution Medicines Stock Lower? (opens in a new tab) Trefis · 12 Nov 2026 15:45
- Revolution Medicines: RASONQUE Is Off To A Strong Start, But Expectations Are High (opens in a new tab) SeekingAlpha · 12 Nov 2026 09:53
- Wall Street Analysts Think Revolution Medicines (RVMD) Could Surge 33.34%: Read This Before Placing a Bet (opens in a new tab) Zacks · 10 Nov 2026 13:55
- Revolution Medicines, Inc. (RVMD) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript (opens in a new tab) SeekingAlpha · 10 Nov 2026 11:01
- Revolution Medicines, Inc. 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 10 Nov 2026 07:19
- Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy? (opens in a new tab) Motley Fool · 08 Nov 2026 16:35
- Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug (opens in a new tab) Motley Fool · 08 Nov 2026 15:35
- Revolution Medicines (RVMD) Rallies On RASONQUE Launch As Fair Value Debate Heats Up (opens in a new tab) Simply Wall St. · 07 Nov 2026 19:12
- Revolution Medicines Stock Gets A Lift From Pancreatic Cancer Drug Launch (opens in a new tab) Simply Wall St. · 07 Nov 2026 09:12
- HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $350 (opens in a new tab) Benzinga · 06 Nov 2026 08:13
- Revolution Medicines Inc (RVMD) Q3 2026 Earnings Call Highlights: RASONQUE's Blockbuster Debut ... (opens in a new tab) GuruFocus.com · 06 Nov 2026 01:07
- Revolution Medicines (RVMD) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 05 Nov 2026 17:43
- RVMD Q3 Earnings & Sales Beat Estimates on Encouraging Rasonque Uptake (opens in a new tab) Zacks · 05 Nov 2026 17:18
- TD Cowen Maintains Buy on Revolution Medicines, Raises Price Target to $270 (opens in a new tab) Benzinga · 05 Nov 2026 16:41
- Revolution’s Rasonque off to best cancer drug launch ‘in history’ (opens in a new tab) BioPharma Dive · 05 Nov 2026 16:21
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 176.35 USD
- Market cap
- 38.1B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
Similar shares
Follow RVMD and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.